Stem Cell Activation Phuket, Thailand: How have athletes been using stem cell therapy
http://www.thanyapurahealth.com/health-services/natural-stem-cell-activationregenerative-therapy/how-have-athletes-been-using-stem-cell-therapy/ Using stem cell therapy treats body issue e.g....

By: Thanyapura Health Centre

See the original post:
Stem Cell Activation Phuket, Thailand: How have athletes been using stem cell therapy - Video

Stem Cell Activation Phuket: What type of clients have you been seeing for stem cell therapy
http://www.thanyapurahealth.com/health-services/natural-stem-cell-activationregenerative-therapy/what-type-of-clients-have-you-been-seeing-for-stem-cell-therapy/ Wide range of client who has...

By: Thanyapura Health Centre

Read the original post:
Stem Cell Activation Phuket: What type of clients have you been seeing for stem cell therapy - Video

The medical community has long thought the heart muscle had zero regenerative ability; once it was damaged or otherwise made ineffective, there was no chance of the body making new cells to replace the old ones. That way of thinking is about to change, however, thanks to a new study from Vanderbilt University.

Cardiac stem cells, cells that can create new heart muscle, have been identified inside arteries. The discovery came about as scientists closely examined endothelial cells that line the inner surface of blood vessels. These cells have been known to generate other cells types during mammalian development.

SEE ALSO: Heart attack signs and symptoms in women

People thought that the same heart you had as a young child, you had as an old man or woman as well, said researcher Antonis Hatzopoulos in a press release. Our study suggests that coronary artery disease could lead to heart failure not only by blocking the arteries and causing heart attacks, but also by affecting the way the heart is maintained and regenerated.

What Hatzopoulos and his team suggest is that while the body is healthy and the heart is functioning at a normal level, the cardiac stem cells in the arteries maintain the heart muscle, regenerating cells as needed. When illness like coronary artery disease or a medical emergency like a heart attack occur, these stem cells stop making healthy muscle tissue and start making scar tissue instead. This switch can further complicate heart failure by creating another way arteries become blocked.

It looks like the same endothelial system generates myocytes (muscle cells) during homeostasis and then switches to generate scar tissue after a myocardial infarction. After injury, regeneration turns to fibrosis, said Hatzopoulos. If we can understand the molecular mechanisms that regulate the fate switch that happens after injury, perhaps we can use some sort of chemical or drug to restore regeneration and make muscle instead of scar. We think there is an opportunity here to improve the way we treat people who come into the clinic after myocardial infarction (heart attack).

SEE ALSO: Heart attacks increase health issues in partners, spouses

The key in future research will be to uncover why the cardiac stem cells in the arteries switch from making healthy cells to making scar tissue cells. By learning to control this switch, experts may be able to one day encourage the body to make new heart tissue after a heart attack or to combat age and other disease issues.

See original here:
Cardiac stem cells have been discovered | Voxxi

MANILA The head of the Catholic Bishops' Conference of the Philippines has a reminder to those taking the ice bucket challenge, which supports research efforts of the Amyotrophic Lateral Sclerosis Association (ALSA).

CBCP president Lingayen-Dagupan Archbishop Socrates Villegas said research on ALS involves the use of stem cells.

''ALS is a degenerative disorder and stem-cells apparently hold out the promise of reversing the death and degeneration of brain cells, in particular,'' Villegas said in a statement.

''Stem cells however are most readily harvested from embryos, and it is in this regard that this type of research is ethically problematic."

Citing the ''Instruction on Respect for Human Life in Its Origin and on the Dignity of Procreation,'' Villegas noted that ''human embryos obtained in vitro are human beings and subjects with rights."

ALS is a progressive neurodegenerative disease that attacks nerve cells and pathways in the brain and spinal cord, which eventually leads to paralysis.

Villegas said the ALS Association said in a statement that ''most stem-cell research in ALS is currently focused on iPS (induced pluripotent stem) cells, which are not burdened with ethical issues."

''We are told that iPS cells are 'induced pluripotent stem cells', stem cells created from skin cells. Such cells would indeed be pluripotent, but would not be embryonic cells,'' the CBCP chief said.

''As such, the ethical objection to the use of embryonic cells, whether harvested from embryos, or obtained through in vitro fertilization, would not arise."

The prelate, however, noted that the ALS Association also admitted that ''iPS cells are used in 'most stem-cell research.'''

See the original post:
Catholics warned about ice bucket challenge

CARLSBAD, CA--(Marketwired - August 28, 2014) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, today announced that Executive Vice President Dr. Simon Craw will present a corporate overview of ISCO and its subsidiaries at two upcoming investment conferences.

Rodman and Renshaw 16th Annual Global Investment Conference:

Date:Wednesday, September 10, 2014 Time:11:40 a.m. ET Location:New York Palace Hotel, New York, NY Room:Kennedy I

Conference details:http://www.meetmax.com//sched/event_23003/~public/conference_home.html?event_id=23003

AEGIS CAPITAL Corp. 2014 Healthcare and Technology Conference:Date:Thursday, September 11, 2014 Time:10:45 a.m. PT Location:The Encore at Wynn, Las Vegas, NV

Conference details:http://www.meetmax.com/sched/event_25932/~public/conference_home.html?event_id=25932

Please contact the conference organizers if you have an interest in attending the conference or if you would like to arrange a meeting with International Stem Cell Corporation's management team.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available atwww.internationalstemcell.com.

To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

See more here:
International Stem Cell Corporation to Present at Two Upcoming Investment Conferences

A lot of individuals are regularly making an effort to find the best medications available today because of the presence of a lot of illnesses in the world. New treatments and variations of old ones are hitting the market because of this growing need of people and one of the newest alternatives to medication that experts have come up with is referred to as induced Pluripotent Stem Cell Therapy, also called iPS Cell Therapy or iPSC Therapy. What is Induced Pluripotent Stem Cell therapy?

Regardless if the entire thing is controversial, a ton of experts continue to show interest when it comes to stem cell therapy. Grown inside the laboratory, people are injected with transmuted cells to replace cells that are unhealthy. This is what science fiction is made of, but now almost a reality.

The thing about stem cell therapy is that it garnered and continues to garner a lot of bad publicity in line with moral and ethical concerns. Several years ago, people saw to it that no further research was done on embryonic stem cells but in 2006, studies were conducted by the Japanese but this time, they used mouse cells. More and more people became mindful of and interested in iPSC because of this shift in events.

About 5 years ago, the University of Wisconsin found a way to study iPSC with the help of adult human cells. The thing about iPSC is that people only had problems with the studies when embryonic stem cells were utilized. Because of such an event, efforts have been made to include iPSC processes in Regenerative or Reparative Medicine.

Various illnesses can affect daily living from arthritis to diabetes to burns and iPSC therapies can be a solution to these provided that adequate research is conducted. What you have here can also be utilized for diseases that are genetic in nature like cancer for example. Aside from dealing with spinal cord issues, there is also a chance that iPSC can be used to cure Parkinsons and Alzheimers disease.

There is so much potential in stem cell therapy. Imagine how much good it will do to mankind if healthy cells may scientifically be produced in laboratories and injected into patients. For people with cancer, the cancerous cells can easily be replaced with the ones that are healthy.

What you have here can change the way people look at disease and pain.. Not having to rely on the human body for cell regeneration is something that can lead to thousands of opportunities in health. There is still a need to perfect current research efforts on the matter but this is surely beyond science fiction.

Other than yet merely in experimental stage, the therapies are also very costly. These therapies need more time for experimentation and more years are necessary if you want to lower the costs of the therapies. But scientists remain hopeful.

One of the most popular therapies in line with stem cells these days is bone marrow transplantation. There are various patients that have different cancers related to the bone marrow or blood and this is what this transplantation serves to treat. It is a risky procedure, however, and may have several complications.

In various countries, scientists get support for this type of research. It may take years before people can rely on iPS Cell therapy on a regular basis but even if this is so, all the hard work will surely be well worth it because of the countless benefits that this form of therapy can bring. Pain and disease will be no match for science once this form of therapy is completed.

Originally posted here:
IPS Cell Therapy | Stem Cells Research

Jilly #39;s Miracle post stem cell therapy at Australind Veterinary Hospital
Jilly pain free following stem cell therapy at Australind Veterinary Hospital.

By: AustralindVet

Read more:
Jilly's Miracle post stem cell therapy at Australind Veterinary Hospital - Video

PUBLIC RELEASE DATE:

28-Aug-2014

Contact: Robert Nellis newsbureau@mayo.edu 507-284-5005 Mayo Clinic

ROCHESTER, Minn. A Mayo Clinic researcher and his collaborators have developed an online analytic tool that will speed up and enhance the process of re-engineering cells for biomedical investigation. CellNet is a free-use Internet platform that uses network biology methods to aid stem cell engineering. Details of CellNet and its application to stem cell engineering are described in two back-to-back papers in the journal Cell.

"This free platform has a broad range of uses for all types of cell-based investigations and can potentially offer help to people working on all types of cancer," says Hu Li, Ph.D., investigator in the Mayo Clinic Center for Individualized Medicine and Department of Molecular Pharmacology & Experimental Therapeutics, and co-lead investigator in the two works. "CellNet will indicate how closely an engineered cell resembles the real counterpart and even suggests ways to adjust the engineering."

The network biology platform contains data on a wide range of cells and details on what is known about those cell types. Researchers say the platform can be applied to almost any study and allows users to refine the engineering process. In the long term, it should provide a reliable short cut to the early phases of drug development, individualized cancer therapies, and pharmacogenetics.

CellNet uses 21 cell types and tissues and data from 56 published human and mouse engineering studies as a basis for analyzing and predicting cell fate and corresponding engineering strategies. The platform also offers classification scores to determine differentiation and conversion of induced pluripotent stem cells. It reveals incomplete conversion of engineered microphages and hepatocytes. CellNet can be used for interrogation of cell fate following expression profiling, by classifying input by cell type, quantifying gene regulatory network status, and identifying aberrant regulators affecting the engineering process. All this is valuable in predicting success of engraftment of cancer tumors in mouse avatars for cancer and drug development research. CellNet can be accessed at cellnet.hms.harvard.edu.

###

Co-lead authors with Dr. Li are Patrick Cahan, Ph.D., and Samantha Morris, Ph.D., of Boston Children's Hospital. The senior investigators are George Q. Daley, M.D., Ph.D., Director of the Stem Cell Transplantation Program at Boston Children's and senior investigator on both studies and James Collins, Ph.D., Core Faculty member at the Wyss Institute and the William F. Warren Distinguished Professor at Boston University, co-senior investigator on one of the studies.

Investigators are supported in part by the National Institutes of Health, specifically, the National Institute of Diabetes and Digestive and Kidney Diseases and the National Heart, Lung, and Blood Institute; the Children's Hospital Stem Cell Program; the Howard Hughes Medical Institute; Alex's Lemonade Stand Foundation; the Ellison Medical Foundation; the Doris Duke Medical Foundation; the Mayo Clinic Center for Individualized Medicine and the Mayo Clinic Center for Regenerative Medicine.

View post:
New tool aids stem cell engineering for medical research

New York, California (PRWEB) August 28, 2014

The Manhattan Regenerative Medicine Medical Group announces a series of free public seminars on the use of adult stem cells for various degenerative and inflammatory conditions. They will be provided by Dr. Thomas A. Gionis, Surgeon-in-Chief, and, Dr. Nia M. Smyrniotis, Medical Director.

The seminars will be held on Wednesday, September 3, 2014, at 2pm and 4pm at the City Limits Diner, at 135 Harvard Avenue, Stamford, CT 06902. Please RSVP at (917) 410-7391.

The Manhattan Regenerative Medicine Medical Group is an affiliate of the Miami Stem Cell Treatment Center, which abide by investigational protocols using adult adipose derived stem cells (ADSCs) which can be deployed to improve patients quality of life for a number of degenerative and chronic inflammatory conditions and diseases. ADSCs are taken from the patients own adipose (fat) tissue (found within a cellular mixture called stromal vascular fraction (SVF). ADSCs are exceptionally abundant in adipose tissue. The adipose tissue is obtained from the patient during a 15 minute mini-liposuction performed under local anesthesia in the doctors office. SVF is a protein-rich solution containing mononuclear cell lines (predominantly adult autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important Growth Factors that facilitate the stem cell process and promote their activity.

ADSCs are the body's natural healing cells - they are recruited by chemical signals emitted by damaged tissues to repair and regenerate the bodys injured cells. The Manhattan Regenerative Medicine Medical Group and the Miami Stem Cell Treatment Center only use Adult Autologous Stem Cells from a person's own fat No embryonic stem cells are used. Current areas of study include: Emphysema, COPD, Asthma, Heart Failure, Parkinsons Disease, Stroke, Multiple Sclerosis, Lupus, Rheumatoid Arthritis, Crohns Disease, and degenerative orthopedic joint conditions. For more information, or if someone thinks they may be a candidate for one of the adult stem cell protocols offered by the Manhattan Regenerative Medicine Medical Group or Miami Stem Cell Treatment Center, they may contact Dr. Gionis or Dr. Nia directly at (917) 410-7391, or see a complete list of the Centers study areas at: http://www.MiamiStemCellsUSA.com or http://www.NYStemCellsUSA.com.

About Manhattan Regenerative Medicine Medical Group and the Miami Stem Cell Treatment Center: The Manhattan Regenerative Medicine Medical Group and The Miami Stem Cell Treatment Center is an affiliate of the Cell Surgical Network (CSN); they are located in Manhattan, NY; Miami, Boca Raton, and Orlando, Florida. We provide care for people suffering from diseases that may be alleviated by access to adult stem cell based regenerative treatment. We utilize a fat transfer surgical technology to isolate and implant the patients own stem cells from a small quantity of fat harvested by a mini-liposuction on the same day. The investigational protocols utilized by the Manhattan Regenerative Medicine Medical Group and the Miami Stem Cell Treatment Center have been reviewed and approved by an IRB (Institutional Review Board) which is registered with the U.S. Department of Health, Office of Human Research Protection; and the study is registered with Clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH). For more information visit our website: http://www.MiamiStemCellsUSA.com or http://www.NYStemCellsUSA.com.

Read more from the original source:
Adult Stem Cell Public Lecture New York Manhattan Regenerative Medicine Medical Group

Stem Cell Therapy as a Treatment Option for Osteoarthritis
Dr. Frank Garcia, board certified orthopedic surgeon with The San Antonio Orthopaedic Group, discusses the use of stem cell therapy in the treatment of osteo...

By: The San Antonio Orthopaedic Group

Continued here:
Stem Cell Therapy as a Treatment Option for Osteoarthritis - Video

Boy Scout Troop 286 Icebucket Challenge for the Scoutmaster
Ice Bucket Challenge Completed! With a whole lot of help from my Scouts! Donation went to the Midwest Stem Cell Therapy Center at KU Med in Kansas City. They do some terrific work there and...

By: Scott Medlock

Link:
Boy Scout Troop 286 Icebucket Challenge for the Scoutmaster - Video

By RTT News, August 27, 2014, 06:53:00 AM EDT

(RTTNews.com) - Asterias Biotherapeutics Inc. (ASTY.OB) said Wednesday that it has received clearance from the U.S. Food and Drug Administration or FDA to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury.

The company stated that the approved trial follows the successful completion of the Phase 1 clinical study of the product, and is designed to assess safety and activity of escalating doses of AST-OPC1 in patients with complete cervical spinal cord injuries, the first targeted indication for AST-OPC1 and the first of future product registration clinical trials.

AST-OPC1 is a population of cells derived from human embryonic stem cells (hESCs) that contains oligodendrocyte progenitor cells (OPCs). OPCs and oligodendrocytes perform supportive functions for nerve cells in the central nervous system. The foundation for this newly cleared Phase 1/2a clinical trial comes from results from the Phase 1 clinical trial of AST-OPC1, which met its primary endpoints of safety and feasibility when administered to five patients with neurologically-complete, thoracic spinal cord injury.

These five patients were administered a low dose of two million AST-OPC1 cells and have been followed to date for 2 to 3 years. No serious adverse events were observed associated with the delivery of the cells, the cells themselves, or the short-course immunosuppression regimen used.

The company noted that the new Phase 1/2a clinical trial will be an open-label, single-arm study testing three escalating doses of AST-OPC1 in 13 patients with subacute, C5-C7, neurologically-complete cervical spinal cord injury. These individuals have essentially lost all sensation and movement below their injury site with severe paralysis of the upper and lower limbs.

AST-OPC1 will be administered 14 to 30 days post-injury. Patients will be followed by neurological exams to assess the safety and activity of the product. Selection of the clinical trial sites is well underway and the Company expects to begin patient enrollment during the first quarter of 2015.

The new clinical trial differs from the original clinical study in that doses up to 10 times higher will be tested. In addition, the trial will focus on patients with neurologically-complete cervical spinal cord injuries. Because of the anatomy of the spinal cord and the existence of more sensitive outcomes measures to assess movement of the arms and hands, it is currently believed that detection of efficacy is much more likely to occur in patients with cervical injuries. It is this patient population that Asterias anticipates will be the target for the first registration clinical trials of AST-OPC1.

The results of the Phase 1/2a clinical trial are expected to provide support for a Phase 2b expansion study that will be conducted to more thoroughly demonstrate safety and efficacy of the product.

For comments and feedback: contact editorial@rttnews.com

View post:
Asterias Gets FDA Clearance To Initiate Phase 1/2a Trial Of AST-OPC1

Manila:

A Philippine Catholic bishop Wednesday urged donors to research on Lou Gehrigs Disease to ensure that their money does not go to unethical studies involving stem cells.

The pastoral guidance was issued as more Filipinos take part in the viral fundraising ice bucket challenge for Lou Gehrigs Disease or Amyotrophic Lateral Sclerosis (ALS), a degenerative disease that affects nerve cells in the brain and spinal cord.

Archbishop Socrates Villegas said donors must make a clear and unequivocal declaration that their donation is made on condition that none of it is applied to research that involves the use of embryonic stem cells in vitro. Catholics who participate in the challenge and who make donations to this research must also demand of fund-raisers and organizers an assurance that none of the donations made will be applied to researches that are ethically reproved, he added.

Villegas said that as long as the research was ethical, the Church would even encourage Catholics to donate, noting, The importance of ALS research cannot be overstated. Research must proceed, for so many suffer. Several top government officials, business leaders and other Filipino personalities have recently taken up the ALS ice bucket challenge, drenching themselves in cold water to raise money for research on the illness.

(This article was published on August 27, 2014)

Visit link:
Filipino bishop urges donors not to support stem cell research

By Ciara Curtin

Jeanne Loring and her Scripps Research Institute colleagues transplanted a set of cells into the spinal cords of mice that had lost use of their hind limbs to multiple sclerosis. As the experimentalists expected, within a week, the mice rejected the cells. But after another week, the mice began to walk.

We thought that they wouldnt do anything, says Loring, who directs theCenter for Regenerative Medicineat Scripps. But as her lab has since shown numerous times, and published in Stem Cell Reports, something that these particular so-called neural precursor cells dobeforethe immune system kicks them out seems to make the mouse better.

The cells Lorings team used are derived from induced pluripotent stem cells, which are mature cells, such as skin cells, that have been coaxed with a combination of chemicals to return to an earlier stage of development.

Induced pluripotent cells, also known as iPS cells, pose a number of opportunities for medicine. For instance, Loring is using iPS cells from Parkinsons disease and multiple sclerosis patients to reconstitute cell types that may be damaged in people with those conditions. She is also using them to test how certain drugs or treatments may affect damaged cells in people with conditions such as autism spectrum disorders.

Loring (front row, center) with the Loring Lab Group at the Center for Regenerative Medicine

Loring says no viable long-term treatments exist for the diseases her team has been working on, including Alzheimers disease, Parkinsons disease, and multiple sclerosis, Thats where the need is, she says.

The neural precursor cells that Loring has been using in the mice with MS are young cells that havent quite gotten to the point of being nerves yet. Only certain types of these cells have such a dramatic Lazarus-like effect on the affected mice, but Lorings team can readily identify them based on DNA analysis.

Even so, theyre not yet ready to treat human MS patients with the approach, she says. First, the researchers want to identify what the cells producea protein, perhaps, or a set of proteinsthat allows the mice to walk.

For other diseases, however, researchers are closer to being ready to transplant working versions of reprogrammed cells into sick people.

Visit link:
Could Reprogrammed Cells Fight 'Untreatable' Diseases?

Stem cell technology pioneer,DefiniGEN Ltdhas joined the Pfizer-inspired European Bank for induced pluripotent stem cells (EBiSC) consortium.

The consortium comprises 26 partners, and has been newly-formed with support from the Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

DefiniGen, a Cambridge University spin-out that has raised millions, represents one of the first commercial opportunities to arise from the universitys expertise in stem cells and is based on the research of Dr Ludovic Vallier, Dr Tamir Rashid and Professor Roger Pedersen of the universitys Anne McLaren Laboratory of Regenerative Medicine.

The EBiSC iPS cell bank will act as a central storage and distribution facility for human iPS cells, to be used by researchers across academia and industry in the study of disease and the development of new therapeutics. DefiniGENs role will be to validate EBiSC iPS cell lines by generating liver hepatocyte cells for toxicology, disease modelling, and regenerative medicine applications.

Dr Marcus Yeo, CEO of DefiniGEN, said: We are delighted to be a part of this ground-breaking consortium which will provide a crucial platform resource to enable the realisation of the full potential of iPS technology.

Conceptualised and coordinated by Pfizer Ltd in Cambridge, UK and managed by Roslin Cells Ltd in Edinburgh, the EBiSC bank aims to become the European go to resource for high quality research grade human iPS cells.

Today, iPS cells are being created in an increasing number of research programmes underway in Europe, but are not being systematically catalogued and distributed at the necessary scale to keep pace with their generation, nor to meet future demand.

The 35 million project will support the initial build of a robust, reliable supply chain from the generation of customised cell lines, the specification to internationally accepted quality criteria and their distribution to any global qualified user, ensuring accessibility to consistent, high quality tools for new medicines development.

Ruth McKernan, CSO of Pfizers Neusentis research unit in Cambridge, said: We are excited to be a part of this precompetitive collaboration to build a sustainable repository of high quality human iPS cell lines.

For many areas of research in academia and in industry, understanding the biological basis of disease heterogeneity is the next horizon. A bank of well-characterised iPS lines with strong relevance to the entire research community will help us all in our mission to bring therapies to patients.

Read more here:
Pfizer buys into Cambridge life science innovation

Scientists who hoped to replicate the results of potentially groundbreaking stem-cell research have been unsuccessful to date, researchers at the Riken Center for Developmental Biology in Kobe, Japan, said Wednesday, according to the Associated Press. Detailed in two papers published in the journal Nature in January, the research was initially heralded as a breakthrough in the field of stem-cell biology, but was later met with skepticism after other institutions attempts to mirror its results failed. The authors of the papers and Nature retracted them in June.

Now, the center behind the papers says its recent efforts to confirm certain aspects of the research have failed. Researchers have conducted 22 experiments thus far, but we could not confirm the emergence of cells in the conditions described in [lead researcher Haruko Obokatas] papers, Riken said in a statement cited by Agence France-Presse. The center anticipates it will continue trying to confirm certain aspects of the research until next March, AP said.

The two papers published in Nature described a simple process for producing stem cells using an acid-based solution. Researchers said they successfully created pluripotent embryonic stem cells -- cells that can be grown into any kind of cell, including human organ tissue -- from mature skin cells. However, it was later revealed that researchers had misrepresented some of their data.

The controversy surrounding the research team who published the papers took an unexpected turn this month when one of the papers authors, Yoshiki Sasai, committed suicide at the Riken institute.

Visit link:
Stem Cell Research Scandal: Japan Lab Could Not Confirm Results Of Controversial Experiment

How can you get the best result after stem cell therapy for autism spectrum disorder
How can you get the best result after stem cell therapy for autism spectrum disorder? In conversation with Dr Alok Sharma (MS, MCh.) Professor of Neurosurgery Head of Department, LTMG Hospital...

By: Neurogen Brain and Spine Institute

The rest is here:
How can you get the best result after stem cell therapy for autism spectrum disorder - Video

STEM CELL THERAPY: with DR ANDREW J. ROCHMAN
Dr. Andrew J Rochman is a leader in advanced surgical techniques, a native New Yorker and a Board-Certified Surgeon. His current undertaking involves promoting an educational advocacy in MODERN...

By: Modern Pain Relief

Here is the original post:
STEM CELL THERAPY: with DR ANDREW J. ROCHMAN - Video

MIAMI - When Bruce Daily woke up after having lumbar surgery a year ago, he realized he couldn't move the right side of his body.

"It took me a long while to figure out I wasn't gonna walk again," he said. "I knew I was down."

Daily, 69, had gone in for lumbar surgery at the University of Miami hospital and had an ischemic stroke while under anesthesia. An ischemic stroke results from an obstruction in a blood vessel that blocks the blood from getting to the brain.

Because he was unconscious, he missed the four-to-five hour-window to apply the tissue plasminogen activator, or tPA, the only medication available to treat ischemic strokes. The medication dissolves the clot, restoring blood flow to the brain.

But while he missed that chance, he was right on time to meet Dr. Dileep Yavagal, a neurosurgeon who practices at the University of Miami and Jackson Memorial hospitals. Yavagal was enrolling patients in RECOVER-stroke, a clinical trial treating recent stroke patients with stem cells from their bone marrow and applying them directly into the carotid artery, one of two arteries that supply the neck and head with blood. Daily was one of 47 patients nationwide who qualified for the study.

The study is funded by Cytomedix, the company that developed the technology to extract stem cells from bone marrow. The firm chose Yavagal to lead a national blind study at the end of 2012.

Yavagal enrolled 13 patients at the University of Miami/Jackson Memorial Hospital, between the end of 2012 and January of 2014. So far, the initial three-month results have revealed that the marrow cells are not doing any damage, and there was no clear difference between those who received the cells and those who didn't. The study's one-year final results will be revealed in January.

"There is severe need for developing treatment for ischemic stroke, and stem cells are the most promising," said Yavagal, whose own research is still in its initial phase, focusing on using a healthy donor's bone marrow stem cells versus the patient's own marrow.

Stroke, the leading cause of adult disability in the United States, and the No. 4 cause of death in the country, causes 130,000 deaths a year in the U.S., according to the Centers for Disease Control and Prevention.

Yavagal, associate professor of clinical neurology and neurosurgery and the director of interventional neurology at the University of Miami's Miller School of Medicine, said that restricted mobility or loss of speech resulting from a moderate to severe stroke can be devastating because patients often become dependent on someone else for daily activities.

Excerpt from:
Can stem cells help mobility after stroke?

By RTT News, August 26, 2014, 06:00:00 PM EDT

(RTTNews.com) - GlaxoSmithKline plc (GSK, GSK.L) said Tuesday the U.S. Food and Drug Administration approved a supplemental New Drug Application for the once-daily use of Promacta (eltrombopag) in patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy.

Severe aplastic anaemia, or SAA, is a blood disorder where the bone marrow fails to make enough red blood cells, white blood cells, and platelets. Eltrombopag, an oral thrombopoietin (TPO) receptor agonist, works by helping to induce proliferation and differentiation of bone marrow stem cells to increase production of blood cells.1

"FDA approval of Promacta addresses a significant treatment need for this very rare but serious blood disorder in those who have failed current treatment options," said Paolo Paoletti, president of Oncology, GSK.

Promacta gained Breakthrough Therapy designation status from the FDA in January 2014 and Priority Review in April 2014. Today's approval by the FDA is based on results from an investigator-sponsored Phase II study conducted by the National Heart, Lung and Blood Institute at the National Institutes of Health.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

Go here to read the rest:
GSK: FDA OKs Promacta SNDA In Patients With Aplastic Anaemia